Overview: Liver Function Advanced Panel
Introduction: The Liver Function Advanced Panel is a diagnostic tool designed for comprehensive liver function assessment using serum samples. In India, chronic liver disease affects ~10-15 percent of adults (~100-150 million), driven by hepatitis B/C (~40 million carriers), NAFLD (~20-30 percent in urban/obese, rising in rural due to metabolic syndrome), alcohol, and toxins. High morbidity from under-testing in rural/low-SES patients with jaundice, ascites, or fatigue, limited labs, delayed antiviral therapy, lifestyle modification, or referral leading to cirrhosis, HCC, or decompensation. Per hepatology practices aligned with ICMR and Indian National Association for Study of the Liver guidelines, the test employs spectrophotometry for 35 liver parameters (enzymes: ALT, AST, ALP, GGT; bilirubin total/direct; proteins: albumin, globulin, total protein; coagulation: PT, INR; electrolytes) over 1-2 days with high accuracy, valuable for staging fibrosis, detecting acute/chronic injury, and monitoring therapy response. This diagnostic falls under liver function screening and targets patients with risk factors (diabetes, alcohol, viral hepatitis, obesity), addressing accurate detection to guide antiviral drugs, abstinence counseling, or transplant evaluation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise liver profiling and reducing cirrhosis/HCC burden. Its serum-based approach ensures reliable multi-parameter assessment.
Other Names: LFT Adv Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.
Historical Milestone: Advanced LFT panel standard; in India, key in NAFLD/hepatitis programs.
Purpose: The test assesses 35 parameters including liver enzymes to guide comprehensive liver function evaluation, stage disease, inform therapy.
Test Parameters: 1â€"35. Liver Enzymes, Bilirubin, Albumin, Globulin, PT, INR, etc.
Pretest Condition: Fasting 10-12 hours recommended; patients should report jaundice or risk factors.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on alcohol use, viral hepatitis, diabetes.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected liver disease including cirrhosis, benefits of assessment, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or recent alcohol can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Elevated enzymes/low albumin/high INR indicate advanced disease, necessitating specialist input.
Specialist Consultation: Hepatologists/gastroenterologists should be consulted for management.
Additional Supporting Tests: Ultrasound, FibroScan, viral serology for confirmation.
Test Limitations: Nonspecific markers; comprehensive approach required.
References: Indian Journal of Gastroenterology 2024, Liver Studies India 2023.
